Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium

Abstract

Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR–SSCP and sequencing. In 47 patients (46.1%), 70 different mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P=0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the α domain and the α-β domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41–45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C→T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C . 1998 Nucleic Acids Res. 26: 256–258

  • Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, Decker HJ . 2000 Cancer Res. 60: 1942–1948

  • Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T . 1999 J. Natl. Cancer Inst. 91: 854–861

  • Bruning T, Weirich G, Hornauer MA, Hofler H, Brauch H . 1997 Arch. Toxicol. 71: 332–335

  • Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA . 1994 Hum. Mol. Genet 3: 1303–1308

  • Day RSD, Babich MA, Yarosh DB, Scudiero DA . 1987 J. Cell Sci. Suppl 6: 333–353

  • Denissenko MF, Chen JX, Tang MS, Pfeifer GP . 1997 Proc. Natl. Acad. Sci. USA 94: 3893–3898

  • Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM, Maher ER . 1994 Hum. Mol. Genet. 3: 2169–2173

  • Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks WB, Isaacs WB, Lehman MI, Zbar B, Linehan WM . 1994 Nat. Genet. 7: 85–90

  • Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I, Holbrook NJ . 1999 Mol. Cell Biol. 19: 1289–1300

  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC . 1994 Cancer Res. 54: 4855–4878

  • Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, McClellan MW, Weng Y, Duan D-SR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AG, Maher ER, Linehan WM, Zbar B, Lerman MI . 1993 Science 260: 1317–1320

  • Lindahl T . 1993 Nature 362: 709–715

  • Mandel JS, McLaughlin JK, Schlehofer B, Mellemgaard A, Helmert U, Lindblad P, McCredie M, Adami HO . 1995 Int. J. Cancer 61: 601–605

  • McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS, Mellemgaard A, Schlehofer B, Niwa S . 1995 Int. J. Cancer 60: 345–349

  • McLaughlin JK, Lindblad P, Mellemgaard A, McCredie M, Mandel JS, Schlehofer B, Pommer W, Adami HO . 1995 Int. J. Cancer 60: 194–198

  • McLaughlin JK, Lipworth L . 2000 Semin. Oncol 27: 115–123

  • Meyer AJ, Hernandez A, Florl AR, Enczmann J, Gerharz CD, Schulz WA, Wernet P, Ackermann R . 2000 Int. J. Cancer 87: 650–653

  • Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD . 1997 Proc. Natl. Acad. Sci. USA 94: 2156–2161

  • Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER . 1997 Am. J. Hum. Genet. 60: 765–771

  • Schoenfeld AR, Davidowitz EJ, Burk RD . 2000a Proc. Natl. Acad. Sci. USA 97: 8507–8512

  • Schoenfeld AR, Parris T, Eisenberger A, Davidowitz EJ, De Leon M, Talasazan F, Devarajan P, Burk RD . 2000b Oncogene 19: 5851–5857

  • Schraml P, Zhaou M, Richter J, Bruning T, Pommer M, Sauter G, Mihatsch MJ, Moch H . 1999 Verh. Dtsch. Ges. Pathol. 83: 218–224

  • Sekido Y, Bader SA, Latif JR, Gnarra AF, Gazdar WM, Linehan B, Zbar MI, Lerman JD, Minna JD . 1994 Oncogene 9: 1599–1604

  • Shiao YH, Rice JM, Anderson LM, Diwan BA, Hard GC . 1998 J. Natl. Cancer Inst. 90: 1720–1723

  • Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D . 1996 Cancer Res. 56: 2299–2301

  • Stebbins CE, Kaelin Jr WG, Pavletich NP . 1999 Science 284: 455–461

  • Thoenes W, Rumpelt HJ, Storkel S . 1990a Klin. Wochenschr. 68: 1102–1111

  • Thoenes W, Storkel S, Rumpelt HJ, Moll R . 1990b Eur. Urol. 18: 6–9

  • Yang K, Lindblad P, Egevad L, Hemminki K . 1999 Cancer Lett. 141: 1–8

  • Yoshida M, Ashida S, Kondo K, Kobayashi K, Kanno H, Shinohara N, Shitara N, Kishida T, Kawakami S, Baba M, Yamamoto I, Hosaka M, Shuin T, Yao M . 2000 Jpn. J. Cancer Res. 91: 204–212

  • Zhuang Z, Gnarra JR, Dudley CF, Zbar B, Linehan WM, Lubensky IA . 1996 Mod. Pathol. 9: 838–842

Download references

Acknowledgements

The study was supported by the Swedish Cancer Society.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kari Hemminki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, X., Yang, K., Lindblad, P. et al. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene 20, 5393–5400 (2001). https://doi.org/10.1038/sj.onc.1204692

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204692

Keywords

This article is cited by

Search

Quick links